Peer-Reviewed Journal Details
Mandatory Fields
Ford, I and Blauw, GJ and Murphy, MB and Shepherd, J and Cobbe, SM and Bollen, ELEM and Buckley, BM and Jukema, JW and Hyland, M and Gaw, A and Lagaay, AM and Perry, IJ and Macfarlane, PW and Norrie, J and Meinders, AE and Sweeney, BJ and Packard, CJ and Westendorp, RGJ and Twomey, C and Stott, DJ and PROSPER Study Grp;
Current controlled trials in cardiovascular medicine
A prospective study of pravastatin in the elderly at risk (PROSPER): Screening experience and baseline characteristics
Optional Fields
Background: PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. Methods: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition. Results: In Scotland, Ireland, and the Netherlands, 23, 770 individuals were screened, and 5, 804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0-9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women). Conclusions: Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.
Grant Details